Matrix metalloproteinase and G protein coupled receptors: Co-conspirators in the pathogenesis of autoimmune disease and cancer

Journal of Autoimmunity

Volumn 33, Issue 3-4, 2009, Pages 214-221

  Eck, Sarah M ^a   Blackburn, Jessica S ^a   Schmucker, Adam C ^a   Burrage, Peter S ^a   Brinckerhoff, Constance E ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Carcinoma associated fibroblasts; Collagenase; CXCR4; Endothelial cells; PAR 1; Rheumatoid arthritis; Synovial fibroblasts

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTICOAGULANT AGENT; BEXAROTENE; CHEMOKINE RECEPTOR CXCR4; E 5555; G PROTEIN COUPLED RECEPTOR; INTERSTITIAL COLLAGENASE; LG 268; MATRIX METALLOPROTEINASE; PEPDUCIN; PEPTIDES AND PROTEINS; PROTEINASE ACTIVATED RECEPTOR 1; RETINOID; RETINOID DERIVATIVE; ROSIGLITAZONE; SCH 53048; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; T 140; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CARCINOGENESIS; CELL ACTIVATION; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; GENE EXPRESSION REGULATION; HUMAN; IMMUNOPATHOGENESIS; LUNG METASTASIS; MELANOMA; METASTASIS; NEOPLASM; OVARY CANCER; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STROMA CELL; VIRUS INFECTION;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BREAST NEOPLASMS; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MATRIX METALLOPROTEINASES; MELANOMA; RECEPTORS, G-PROTEIN-COUPLED; SKIN NEOPLASMS; STROMAL CELLS;

EID: 71649085437     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.09.011     Document Type: Article

References (89)

1. Sporn M.B., and Harris Jr. E.D. Proliferative diseases. Am J Med 70 6 (1981 Jun) 1231-1235
2. Brinckerhoff C.E., and Matrisian L.M. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3 3 (2002 Mar) 207-214
3. Burrage P.S., and Brinckerhoff C.E. Molecular targets in osteoarthritis: metalloproteinases and their inhibitors. Curr Drug Targets 8 2 (2007 Feb) 293-303
4. Burrage P.S., Mix K.S., and Brinckerhoff C.E. Matrix metalloproteinases: role in arthritis. Front Biosci 11 (2006) 529-543
5. Firestein G.S. Etiology and pathogenesis of rheumatoid arthritis (1997), W.B. Saunders, Philadelphia
6. Martel-Pelletier J., Welsch D.J., and Pelletier J.P. Metalloproteases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol 15 5 (2001 Dec) 805-829
7. Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 11 (2006) 479-491
8. Burrage P.S., Huntington J.T., Sporn M.B., and Brinckerhoff C.E. Regulation of matrix metalloproteinase gene expression by a retinoid X receptor-specific ligand. Arthritis Rheum 56 3 (2007 Mar) 892-904
9. Burrage P.S., Schmucker A.C., Ren Y., Sporn M.B., and Brinckerhoff C.E. Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression. Arthritis Res Ther 10 6 (2008) R139
10. Bhowmick N.A., Neilson E.G., and Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 432 7015 (2004 Nov 18) 332-337
11. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 5564 (2002 Mar 29) 2387-2392
12. Mueller M.M., and Fusenig N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4 11 (2004 Nov) 839-849
13. Serini G., and Gabbiani G. Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res 250 2 (1999 Aug 1) 273-283
14. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315 26 (1986 Dec 25) 1650-1659
15. Desmouliere A., Guyot C., and Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 48 5-6 (2004) 509-517
16. Ronnov-Jessen L., Petersen O.W., and Bissell M.J. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76 1 (1996 Jan) 69-125
17. Sappino A.P., Skalli O., Jackson B., Schurch W., and Gabbiani G. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int J Cancer 41 5 (1988 May 15) 707-712
18. Holliday D.L., Hughes S., Shaw J.A., Walker R., and AJones J.L. Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Res 9 5 (2007) R67
19. Mishra P.J., Mishra P.J., Humeniuk R., Medina D.J., Alexe G., Mesirov J.P., et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 68 11 (2008 Jun 1) 4331-4339
20. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121 3 (2005 May 6) 335-348
21. Sugimoto H., Mundel T.M., Kieran M.W., and Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5 12 (2006 Dec) 1640-1646
22. Orimo A., and Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 5 15 (2006 Aug) 1597-1601
23. Mueller L., Goumas F.A., Affeldt M., Sandtner S., Gehling U.M., Brilloff S., et al. Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment. Am J Pathol 171 5 (2007 Nov) 1608-1618
24. Sato T., Sakai T., Noguchi Y., Takita M., Hirakawa S., and Ito A. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol 92 1 (2004 Jan) 47-56
25. Eck S., Cote A.L., Winkelman W.D., and Brinckerhoff C.E. CXCR4 and MMP-1 are elevated in breast carcinoma-associated fibroblasts and in normal mammary fibroblasts exposed to factors secreted by breast cancer cells. Mol Can Res 7 7 (2009 Jul) 1033-1044
26. de Jong J.S., van Diest P.J., van der Valk P., and Baak J.P. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: an inventory in search of autocrine and paracrine loops. J Pathol 184 1 (1998 Jan) 44-52
27. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 6824 (2001 Mar 1) 50-56
28. Garcia-Vicuna R., Gomez-Gaviro M.V., Dominguez-Luis M.J., Pec M.K., Gonzalez-Alvaro I., Alvaro-Gracia J.M., et al. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum 50 12 (2004 Dec) 3866-3877
29. Hashimoto N., Jin H., Liu T., Chensue S.W., and Phan S.H. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 113 2 (2004 Jan) 243-252
30. Friedl P., and Wolf K. Proteolytic and non-proteolytic migration of tumour cells and leucocytes. Biochem Soc Symp 70 (2003) 277-285
31. Eck S.M., Hoopes P.J., Petrella B.L., Coon C.I., and Brinckerhoff C.E. Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat (2008 Jul 3)
32. Wyatt C.A., Geoghegan J.C., and Brinckerhoff C.E. Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 cells: effects on matrix destruction and tumor growth. Cancer Res 65 23 (2005 Dec 1) 11101-11108
33. Giambernardi T.A., Grant G.M., Taylor G.P., Hay R.J., Maher V.M., McCormick J.J., et al. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 16 8 (1998 Mar) 483-496
34. Boire A., Covic L., Agarwal A., Jacques S., Sherifi S., and Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120 3 (2005 Feb 11) 303-313
35. Blackburn J.S., Rhodes C.H., Coon C.I., and Brinckerhoff C.E. RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res 67 22 (2007 Nov 15) 10849-10858
36. Blackburn J.S., and Brinckerhoff C.E. Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis. Am J Pathol 173 6 (2008 Dec) 1736-1746
37. Ossovskaya V.S., and Bunnett N.W. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 84 2 (2004 Apr) 579-621
38. Rickles F.R., Patierno S., and Fernandez P.M. Tissue factor, thrombin, and cancer. Chest 124 3 Suppl (2003 Sep) 58S-68S
39. Tsopanoglou N.E., and Maragoudakis M.E. Role of thrombin in angiogenesis and tumor progression. Semin Thromb Hemost 30 1 (2004 Feb) 63-69
40. Hollenberg M.D., and Compton S.J. International union of pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 54 2 (2002 Jun) 203-217
41. Maragoudakis M.E., Tsopanoglou N.E., and Andriopoulou P. Mechanism of thrombin-induced angiogenesis. Biochem Soc Trans 30 2 (2002 Apr) 173-177
42. Furuhashi I., Abe K., Sato T., and Inoue H. Thrombin-stimulated proliferation of cultured human synovial fibroblasts through proteolytic activation of proteinase-activated receptor-1. J Pharmacol Sci 108 1 (2008 Sep) 104-111
43. Hirano F., Kobayashi A., Hirano Y., Nomura Y., Fukawa E., and Makino I. Thrombin-induced expression of RANTES mRNA through protease activated receptor-1 in human synovial fibroblasts. Ann Rheum Dis 61 9 (2002 Sep) 834-837
44. Kirilak Y., Pavlos N.J., Willers C.R., Han R., Feng H., Xu J., et al. Fibrin sealant promotes migration and proliferation of human articular chondrocytes: possible involvement of thrombin and protease-activated receptors. Int J Mol Med 17 4 (2006 Apr) 551-558
45. Yang Y.H., Hall P., Little C.B., Fosang A.J., Milenkovski G., Santos L., et al. Reduction of arthritis severity in protease-activated receptor-deficient mice. Arthritis Rheum 52 4 (2005 Apr) 1325-1332
46. Goerge T., Barg A., Schnaeker E.M., Poppelmann B., Shpacovitch V., Rattenholl A., et al. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res 66 15 (2006 Aug 1) 7766-7774
47. Nesi A., and Fragai M. Substrate specificities of matrix metalloproteinase 1 in PAR-1 exodomain proteolysis. Chembiochem 8 12 (2007 Aug 13) 1367-1369
48. Blackburn JS, Lui I, Coon CI, Brinckerhoff CE. An autocrine matrix metalloproteinase/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis. Oncogene 2009;[Epub ahead of print].
49. Brinckerhoff C.E., and Sporn M.B. Retinoids and rexinoids for the 21st century: a brave new world for arthritis. J Rheumatol 30 2 (2003 Feb) 211-213
50. Hansen I.B., Ellingsen T., Hornung N., Poulsen J.H., Lottenburger T., and Stengaard-Pedersen K. Plasma level of CXC-chemokine CXCL12 is increased in rheumatoid arthritis and is independent of disease activity and methotrexate treatment. J Rheumatol 33 9 (2006 Sep) 1754-1759
51. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343 22 (2000 Nov 30) 1594-1602
52. Loeffler M., Kruger J.A., Niethammer A.G., and Reisfeld R.A. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 116 7 (2006 Jul) 1955-1962
53. Smalley K.S., Lioni M., and Herlyn M. Targeting the stromal fibroblasts: a novel approach to melanoma therapy. Expert Rev Anticancer Ther 5 6 (2005 Dec) 1069-1078
54. Milner J.M., and Cawston T.E. Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. Curr Drug Targets Inflamm Allergy 4 3 (2005 Jun) 363-375
55. Schroen D.J., and Brinckerhoff C.E. Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms. Gene Expr 6 4 (1996) 197-207
56. Beehler B.C., Hei Y.J., Chen S., Lupisella J.A., Ostrowski J., Starrett J.E., et al. Inhibition of disease progression by a novel retinoid antagonist in animal models of arthritis. J Rheumatol 30 2 (2003 Feb) 355-363
57. Cuzzocrea S., Mazzon E., Dugo L., Patel N.S., Serraino I., Di Paola R., et al. Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Arthritis Rheum 48 12 (2003 Dec) 3544-3556
58. Fahmi H., Pelletier J.P., Di Battista J.A., Cheung H.S., Fernandes J.C., and Martel-Pelletier J. Peroxisome proliferator-activated receptor gamma activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1. Osteoarthr Cartil 10 2 (2002 Feb) 100-108
59. François M., Richette P., Tsagris L., Raymondjean M., Fulchignoni-Lataud M.C., Forest C., et al. Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element. J Biol Chem 279 27 (2004 Jul 2) 28411-28418
60. Kobayashi T., Notoya K., Naito T., Unno S., Nakamura A., Martel-Pelletier J., et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. Arthritis Rheum 52 2 (2005 Feb) 479-487
61. Shiojiri T., Wada K., Nakajima A., Katayama K., Shibuya A., Kudo C., et al. PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol 448 2-3 (2002 Jul 19) 231-238
62. Ij A., Tan N.S., Gelman L., Kersten S., Seydoux J., Xu J., et al. In vivo activation of PPAR target genes by RXR homodimers. EMBO J 23 10 (2004 May 19) 2083-2091
63. Crowe D.L., and Chandraratna R.A. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 6 5 (2004) R546-R555
64. Forman B.M. The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem 277 15 (2002 Apr 12) 12503-12506
65. Consoli A., and Devangelio E. Thiazolidinediones and inflammation. Lupus 14 9 (2005) 794-797
66. Henikoff S. Histone modifications: combinatorial complexity or cumulative simplicity?. Proc Natl Acad Sci U S A 102 15 (2005 Apr 12) 5308-5309
67. Shia W.J., Pattenden S.G., and Workman J.L. Histone H4 lysine 16 acetylation breaks the genome's silence. Genome Biol 7 5 (2006) 217
68. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 11 (2004 Sep 9) 1106-1118
69. Dragnev K.H., Petty W.J., Shah S.J., Lewis L.D., Black C.C., Memoli V., et al. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res 13 6 (2007 Mar 15) 1794-1800
70. Duvic M., Martin A.G., Kim Y., Olsen E., Wood G.S., Crowley C.A., et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 137 5 (2001 May) 581-593
71. Read W.L., Baggstrom M.Q., Fracasso P.M., and Govindan R. A phase I study of bexarotene and rosiglitazone in patients with refractory cancers. Chemotherapy 54 3 (2008) 236-241
72. Khan A., Greenman J., and Archibald S.J. Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates. Curr Med Chem 14 21 (2007) 2257-2277
73. Taborga M., Corcoran K.E., Fernandes N., Ramkissoon S.H., and Rameshwar P. G-coupled protein receptors and breast cancer progression: potential drug targets. Mini Rev Med Chem 7 3 (2007 Mar) 245-251
74. Tamamura H., and Fujii N. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert Opin Ther Targets 9 6 (2005 Dec) 1267-1282
75. Agarwal A., Covic L., Sevigny L.M., Kaneider N.C., Lazarides K., Azabdaftari G., et al. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Ther 7 9 (2008 Sep) 2746-2757
76. Smyth S.S., Woulfe D.S., Weitz J.I., Gachet C., Conley P.B., Goodman S.G., et al. G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol 29 4 (2009 Apr) 449-457
77. Gondi CSRao J.S. Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol (2009 Apr 23)
78. Villares G.J., Zigler M., Wang H., Melnikova V.O., Wu H., Friedman R., et al. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res 68 21 (2008 Nov 1) 9078-9086
79. Shoenfeld Y., Selmi C., Zimlichman E., and Gershwin M.E. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 31 (2008) 325-330
80. Mackay I.R., Leskovsek N.V., and Rose N.R. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 30 (2008) 5-11
81. Eaton W.W., Rose N.R., Kalaydjian A., Pedersen M.G., and Mortensen P.B. Epidemiology of autoimmune diseases in Denmark. J Autoimmun 29 (2007) 1-9
82. Rose N.R. The year in immunology 2008. Preface. Ann N Y Acad Sci (2008 Nov)
83. Cihakova D., and Rose N.R. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol 99 (2008) 95-114
84. Li H.S., Ligons D.L., Rose N.R., and Guler M.L. Genetic differences in bone marrow-derived lymphoid lineages control susceptibility to experimental autoimmune myocarditis. J Immunol 180 11 (2008 Jun 1) 7480-7484
85. Burek C.L., and Rose N.R. Autoimmune thyroiditis and ROS. Autoimmun Rev 7 7 (2008 Jul) 530-537
86. Twarog F.J., and Rose N.R. Transfer of autoimmune thyroiditis of the rat with lymph node cells. J Immunol 104 6 (1970 Jun) 1467-1475
87. Whittingham S., Rowley M.J., and Gershwin M.E. A tribute to an outstanding immunologist - Ian Reay Mackay. J Autoimmun 31 (2008) 197-200
88. Gershwin M.E. Bone marrow transplantation, refractory autoimmunity and the contributions of Susumu Ikehara. J Autoimmun 30 (2008) 105-107
89. Blank M., and Gershwin M.E. Autoimmunity: from the mosaic to the kaleidoscope. J Autoimmun 30 (2008) 1-4